<DOC>
	<DOCNO>NCT00949702</DOCNO>
	<brief_summary>This open-label single arm study ass efficacy , safety tolerability Vemurafenib previously treat patient metastatic melanoma . Patients receive oral Vemurafenib [ RG7204 ; PLEXXIKON : PLX4032 ] dose 960 mg b.i.d . continuously disease progression withdrawal study assess regular interval tumour response tolerability . Target sample size &lt; 100 patient .</brief_summary>
	<brief_title>A Study Vemurafenib Previously Treated Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>adult patient &gt; /=18 year age histologically confirm metastatic melanoma ( Stage IV , AJCC ) patient must complete fail least one prior standard care regimen ( e.g . DTIC , temozolomide , etc . ) BRAF V600E positive mutation ( Roche CoDx BRAF mutation assay ) measurable disease RECIST criterion negative pregnancy test , fertile men woman , effective contraception treatment 6 month completion active CNS metastasis CT/MRI within 28 day prior enrollment history know carcinomatous meningitis previous treatment BRAF ( sorafenib allow ) MEK inhibitor cardiac dysrhythmias &gt; 2 NCI CTCAE treatment drug dysrhythmic potential uncontrolled hypertension ( &gt; 150/100mmHg ) despite optimal medical therapy infectious disease include HIV , HBV HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>